MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Allogene Therapeutics Inc

Cerrado

SectorSanidad

1.25 1.63

Resumen

Variación precio

24h

Actual

Mínimo

1.24

Máximo

1.31

Métricas clave

By Trading Economics

Ingresos

206K

-60M

Margen de beneficios

272,450

Empleados

226

EBITDA

-302K

-56M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+593.6% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

26M

282M

Apertura anterior

-0.38

Cierre anterior

1.25

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

154 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Allogene Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 jul 2025, 21:01 UTC

Ganancias

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 jul 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

18 jul 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

18 jul 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Basic Materials Roundup: Market Talk

18 jul 2025, 20:46 UTC

Ganancias

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 jul 2025, 20:39 UTC

Adquisiciones, fusiones, absorciones

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 jul 2025, 20:36 UTC

Ganancias

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 jul 2025, 20:16 UTC

Adquisiciones, fusiones, absorciones

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 jul 2025, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

18 jul 2025, 20:02 UTC

Charlas de Mercado

Gold Higher to Close Out Week -- Market Talk

18 jul 2025, 19:14 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 jul 2025, 19:06 UTC

Charlas de Mercado

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 jul 2025, 18:24 UTC

Ganancias

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 jul 2025, 18:19 UTC

Ganancias

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 jul 2025, 18:11 UTC

Adquisiciones, fusiones, absorciones

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 jul 2025, 18:11 UTC

Ganancias

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 jul 2025, 17:35 UTC

Charlas de Mercado

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 jul 2025, 16:29 UTC

Charlas de Mercado

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 jul 2025, 16:28 UTC

Adquisiciones, fusiones, absorciones

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 jul 2025, 16:22 UTC

Ganancias

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 jul 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

18 jul 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

18 jul 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

18 jul 2025, 16:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Energy & Utilities Roundup: Market Talk

18 jul 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Basic Materials Roundup: Market Talk

18 jul 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

18 jul 2025, 16:04 UTC

Ganancias

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 jul 2025, 15:58 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

18 jul 2025, 15:58 UTC

Charlas de Mercado

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 jul 2025, 15:47 UTC

Charlas de Mercado
Ganancias

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Comparación entre iguales

Cambio de precio

Allogene Therapeutics Inc previsión

Precio Objetivo

By TipRanks

593.6% repunte

Estimación a 12 Meses

Media 8.67 USD  593.6%

Máximo 14 USD

Mínimo 4 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Allogene Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

11

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.18 / 1.69Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

154 / 376 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.